2007 Rate Card

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Data from the TiNivo-2 trial showed a median progression-free survival of 5.7 months in the tivozanib plus nivolumab arm vs 7.4 months in tivozanib monotherapy arm.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

“As health care professionals, we should take a multidisciplinary approach to addressing the stress of a cancer diagnosis by helping mitigate financial toxicity, treatment burden, and emotional impact on both the patient and their family," says Mouneeb M. Choudry, MD.

“NSD2 is a cancer specific collaborator of the androgen receptor that essentially rewires its activity to support prostate cancer development," says Abhijit Parolia, PhD,